All Fiocruz actions are oriented towards societal needs. We do this in various ways by deploying different technologies: hard technologies to prevent, to detect and to treat diseases; and soft technologies with social purposes.
Here are some examples of Fiocruz projects that has helped to improve not only Brazilian citizen’s life, but also helped the world to fight several diseases, and increase health standards worldwide.
The technologies with social purposes are set of techniques, transformative methodologies, developed and/or applied in the interaction with the population and appropriate for it, which represent solutions for social inclusion and improvement of living conditions.
Click at the images for description of the projects
OTSS - Bocaina
HMB - Fiocruz
Healthcare
Here we are presenting some examples of diseases we are fighting among various tropical, rare, neglected and chronic diseases
Click at the images for description of the projects
WMP
HIV
Hanseniasis
Malaria
Cancer
Autoimune
Arboviruses
Among the large range of activities done by the several institutes at Fiocruz, the development and manufacturing of pharmaceuticals, vaccines, diagnostics and biological medicines has a very important role in the Brazilian Health System. By providing affordable and sustainable products due to local manufacturing, Fiocruz supports the Brazilian Government pharmaceutical assistance programs, having a daily impact on people`s health.
Such challenges are part of the work done by two Fiocruz institutes: Bio-Manguinhos and Farmanguinhos. Both institutes work in collaboration within Fiocruz innovation ecossystem, as well as with other organizations around the world.
Bio-Manguinhos is the biggest and most modern governmental owned institute for R&D and manufacturing of vaccines, in vitro diagnostics (IVDs) and biopharmaceuticals in Brazil. As part of Fiocruz system, Bio-Manguinhos plays a strategic role in supply of several pediatric vaccines for around 3 million newborns per year in Brazil, and is a WHO pre-qualified manufacturer to supply vaccines for more than 70 countries worldwide, according to United Nations Agencies request, mostly PAHO and UNICEF. Regarding diagnostics, Bio-Manguinhos delivers 17 IVDs for several diseases and has an important role for the surveillance system and for safe blood transfusion. In biopharmaceuticals, Bio-Manguinhos has invested in products that has both major impact for the sustainability of MoH medicines acquisition and for the population’s health.
Farmanguinhos contributes with nearly 40% of the drug purchased by the Ministry of Health from public labs, representing 5% of Ministry of Health expenditures with medicines purchase. This means that Fiocruz is responsible to maintain sustainable and affordable medicines supply.
Farmanguinhos generates savings to the government budget, especially due to the manufacturing of medicines used in HIV/AIDS treatment, allowing the government to regulate prices charged by other laboratories and even to determine compulsory licensing of medicines, as occurred with Efavirenz, an antiretroviral.
In order to be successful in R&D in biologicals, having scaling-up capabilities and infrastructure is key. Such capabilities allow closing the gap between drug discovery and market introduction. Fiocruz Pilot Plant will provide CDMO services for clinical trials batches and other scaling-up services attending not only Fiocruz biological products development ecosystem, but also other institutions, public and private, in the Brazilian Health Industry Complex.